The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2024 | Post-hoc analysis of TOURMALINE-MM1 data while adjusting for subsequent therapies
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the results of a post-hoc analysis of data from the TOURMALINE-MM1 trial (NCT01564537) that adjusted for subsequent therapies received by patients following progression. In the initial readout from the trial, no benefit to overall survival (OS) was found with the addition of ixazomib to a combination of lenalidomide and dexamethasone in patients with relapsed/refractory (R/R) multiple myeloma (MM). However, when adjusting for post-progression therapies, OS was greater in those patients receiving the triplet regimen. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
